INC boosts presence in Japan, Asia with new move

After recently merging with fellow CRO InVentiv in a new company worth around $7.4 billion, INC says it is now focused on growing its Asia presence with moves and an expansion.

It says it has outgrown its former digs and has moved into a more spacious Tokyo, Japan office in what it says “supports the company’s long-term growth strategy both in Japan and across the Asia/Pacific region.”

In the last two and a half years, INC says its Tokyo ops “rapidly outgrew” its old offices due to a more than fourfold increase in head count.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“Our continued expansion in Tokyo demonstrates our commitment to becoming the global ‘CRO of Choice’ within this vibrant pharmaceutical market for regional and global clinical trials,” said Miranda Porter, Ph.D., SVP of clinical development, Tokyo.

RELATED: INC Research and inVentiv Health merge in another major CRO deal

“Our employees provide global expertise within our therapeutically aligned delivery model while providing local experience and knowledge of Japan’s regulatory, healthcare and cultural environments. Our continued expansion in the country is making a strong contribution to INC’s overall growth.”

INC’s experience from Tokyo focuses on CNS and general medicine and cancer trials.

This comes around two months from its large and unexpected deal to merge with InVentiv. The new company will be headquartered in Raleigh, North Carolina, (where INC is based) and said at the time that it would have a “significant presence in the Northeast corridor of the United States, and operations worldwide, including in Asia and Europe.”

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.